AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is a biotechnology company primarily engaged in the research and development of targeted therapeutics to improve the immune system. The firm's leading product, Ampligen, is an immuno-modulatory double-stranded RNA drug developed for the treatment of certain immune-deficiency related diseases and viral infections. AIM ImmunoTech is also actively involved in ongoing research efforts targeting cancers and chronic fatigue syndrome (CFS). The company operates primarily within the biotech and pharmaceutical industries, playing an influential role in pioneering new medical treatments through its innovative approaches to immunotherapy. Headquartered in Florida, AIM ImmunoTech Inc. contributes to critical healthcare advancements by facilitating treatments that harness and enhance the body’s natural defense mechanisms, and is part of the broader movement toward precision medicine and personalized healthcare solutions in the market.